## ClinicalTrials.gov Search Results 06/17/2022

	Title	Status	Study Results	Conditions	Interventions	Locations
1	Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio +Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study	Completed	Has Results	Pulmonary Disease, Chronic Obstructive	Drug: Tiotropium bromide + Olodaterol     Device: Sp(t)iolto® Respimat®	AETION inc, New York, New York, United States
2	Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies	Completed	Has Results	Pulmonary Disease, Chronic Obstructive	Drug: fluticasone propionate/salmeterol xinafoate combination     Drug: Other maintenance Treatments (OMT)	
3	Early Detection of COPD Patients in GOLD 0 (Smokers) Population	Completed	No Results Available	•COPD     •Smoking     •Other Diagnoses, Comorbidities, and Complications		<ul> <li>University Hospital Osijek, Osijek, Slavonsko-Baranjska, Croatia</li> <li>General Hospital Dubrovnik, Dubrovnik, Croatia</li> <li>University Hospital Rijeka, Rijeka, Croatia</li> <li>Clinical Hospital Center, Split, Split, Croatia</li> <li>Children's Hospital Srebrnjak, Zagreb, Croatia</li> <li>Institute for Medical Research and Occupational Health, Zagreb, Zagreb, Croatia</li> </ul>
4	Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD	Completed	No Results Available	•COPD Exacerbation	<ul> <li>Drug: Levofloxacin 1 tablet 500 mg once a day</li> <li>Drug: Prulifloxacin 1 tablet 600 mg once a day</li> </ul>	<ul> <li>Hospita "San Francesco Caracciolo", Agnone, Italy</li> <li>Hospital of Alghero, Alghero, Italy</li> <li>Hospital "Cardinal Massaia", Asti, Italy</li> <li>Hospital "Fatebenefratelli", Benevento, Italy</li> <li>Hospital of Bordighera, Bordighera, Italy</li> <li>Hospital "San Giovanni di Dio", Cagliari, Italy</li> <li>Hospital "Pugliese-Ciaccio", Catanzaro, Italy</li> <li>Hospital "L.Parodi Delfino", Colleferro, Italy</li> <li>Hospita "San Giovanni di Dio", Crotone, Italy</li> <li>Hospital "E.Profili" of Fabriano, Fabriano, Italy</li> <li>and 15 more</li> </ul>
5	Continuous Monitoring of Patients With Chronic Obstructive Pulmonary Disease	Completed	No Results Available	•COPD		Department of Respiratory Medicine & Allergology, Skånes universitetssjukhus Lund, Lund, Sweden
6	Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan	Completed	No Results Available	•Chronic Obstructive Pulmonary Disease (COPD)		<ul> <li>Kazakhstan Academy of Preventive Medicine, Almaty, Kazakhstan</li> </ul>
7	Development of an Optimal Antibiotic Regime for Long-term Therapy in Stable Chronic Obstructive Pulmonary Disease (COPD)	Unknown status	No Results Available	Chronic Obstructive Pulmonary Disease (COPD).	<ul><li>Drug: Moxifloxacin</li><li>Drug: Azithromycin</li><li>Drug: Doxycycline</li><li>Drug: Placebo</li></ul>	Academic Unit of Respiratory Medicine, Royal Free Hospital, London, United Kingdom
8	The Short Physical Performance Battery in Chronic Obstructive Pulmonary Disease (COPD)	Completed	No Results Available	Chronic Obstructive Pulmonary Disease	Other: Pulmonary rehabilitation	LHL-klinikkene Glittre, Hakadal, Norway
9	Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists	Completed	Has Results	Pulmonary Disease, Chronic Obstructive		Aarhus Universitets hospital Skejby, Aarhus, Denmark
10	Does Chronic Obstructive Lung Disease Influence the Cognitive Function	Not yet recruiting	No Results Available	Chronic Obstructive Pulmonary Disease	Other: driving simulator	

	Title	Status	Study Results	Conditions	Interventions	Locations
11	Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs	Completed	Has Results	Pulmonary Disease, Chronic Obstructive	Device: Relvar ELLIPTA     Device: Symbicort TURBUHALER     Device: Seretide DISKUS     Device: Spiriva HANDIHALER     Device: BREEZHALER     Device: Incruse ELLIPTA     Device: Anoro ELLIPTA	<ul> <li>GSK Investigational Site, Beek En Donk, Netherlands</li> <li>GSK Investigational Site, Beek, Netherlands</li> <li>GSK Investigational Site, Eindhoven, Netherlands</li> <li>GSK Investigational Site, Hengelo, Netherlands</li> <li>GSK Investigational Site, Hoorn, Netherlands</li> <li>GSK Investigational Site, Kloosterhaar, Netherlands</li> <li>GSK Investigational Site, Nijverdal, Netherlands</li> <li>GSK Investigational Site, Rotterdam, Netherlands</li> <li>GSK Investigational Site, Zutphen, Netherlands</li> <li>GSK Investigational Site, Northwood, Middlesex, United Kingdom</li> <li>and 3 more</li> </ul>
12	Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers	Completed	Has Results	Pulmonary Disease, Chronic Obstructive	Drug: olodaterol     Drug: tiotropium     Drug: Placebo	<ul> <li>•1237.7.49004 Boehringer Ingelheim Investigational Site, Berlin, Germany</li> <li>•1237.7.49005 Boehringer Ingelheim Investigational Site, Berlin, Germany</li> <li>•1237.7.49007 Boehringer Ingelheim Investigational Site, Frankfurt, Germany</li> <li>•1237.7.49002 Boehringer Ingelheim Investigational Site, Großhansdorf, Germany</li> <li>•1237.7.49003 Boehringer Ingelheim Investigational Site, Hamburg, Germany</li> <li>•1237.7.49001 Boehringer Ingelheim Investigational Site, Weinheim, Germany</li> </ul>
13	A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol	Completed	No Results Available	Pulmonary Disease, Chronic Obstructive	Device: Trelegy Ellipta     Device: Stiolto Respimat     Drug: Furoate/Umeclidinium/Vilanterol     Drug: Tiotropium Bromide/Olodaterol	Optum, Eden Prairie, Minnesota, United States
14	The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus	Completed	Has Results	Pulmonary Disease, Chronic Obstructive	Drug: Tiotropium     Drug: Olodaterol     Drug: Fluticasone propionate     Drug: Salmeterol	<ul> <li>Jasper Summit Research, LLC, Jasper, Alabama, United States</li> <li>Clinical Trial Connection, Flagstaff, Arizona, United States</li> <li>California Research Medical Group, Inc., Fullerton, California, United States</li> <li>Allergy and Asthma Specialists Medical Group, Huntington Beach, California, United States</li> <li>California Medical Research Associates Inc., Northridge, California, United States</li> <li>IMMUNOe Research Centers, Centennial, Colorado, United States</li> <li>Clinical Research of West Florida, Inc., Clearwater, Florida, United States</li> <li>Bioclinica Research, Orlando, Florida, United States</li> <li>IMIC, Inc, Palmetto Bay, Florida, United States</li> <li>Clinical Research of West Florida, Inc., Tampa, Florida, United States</li> <li>And 35 more</li> </ul>

	Title	Status	Study Results	Conditions	Interventions	Locations
15	Risk of Re-Hospitalization in Patients With Chronic	Completed	No Results Available	Pulmonary Disease, Chronic Obstructive	•Drug: FSC	
	Obstructive Pulmonary Disease (COPD) Post Exacerbation				•Drug: ACs	
16	Correlation of Airflow Limitation and Other Respiratory Characteristics With Radiologic Changes of Lung Structure	Unknown status	No Results Available	Chronic Obstructive Pulmonary Disease		Hillel Yaffe Medical Center, Hadera, Israel
17	Cardiorespiratory Diagnostic Study	Enrolling by invitation	No Results Available	•COPD     •Asthma     •Lung Cancer     •Anemia     •Congestive Cardiac Failure     •Bronchiectasis     •Interstitial Lung Disease     •Long COVID     •Upper Respiratory Disease     •Healthy	Device: N-Tidal C handset	Modality Partnership, Birmingham, West Midlands, United Kingdom
18	Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)	Completed	No Results Available	Pulmonary Disease, Chronic Obstructive	<ul> <li>Drug: Long-acting muscarinic antagonist+ Long-acting beta2 adrenoceptor agonist</li> <li>Drug: Triple combination of Free or fixed Long-acting muscarinic antagonist+ Long- acting beta2 adrenoceptor agonist + inhalative corticosteroids</li> </ul>	<ul> <li>Dr. Graubner, Bad Sachsa, Germany</li> <li>Dr. Junggeburth, Bad Wörishofen, Germany</li> <li>Dr. Heinz, Bergisch Gladbach, Germany</li> <li>Praxis E. Hossbach, Berkatal, Germany</li> <li>Praxis an der Oper, Berlin, Germany</li> <li>Dr. Urban, Berlin, Germany</li> <li>Praxis A.Sahan/S. Erbil-Sahan, Berlin, Germany</li> <li>Dr. Kopf, Berlin, Germany</li> <li>Dres. Pabst/Schlünz, Bonn, Germany</li> <li>Dres. Bartels/Bartels, Breuberg, Germany</li> <li>and 65 more</li> </ul>
19	Tobacco Intensive Motivational and Estimate Risk	Completed	No Results Available	Severe Mental Disorder  Smoking Cessation  COPD	Device: personalized information about lung damage	Fernando Sarramea Crespo, Cordoba, Spain
20	The Natural History of Small Airways Physiology in Diseased and Healthy States	Completed	Has Results	<ul> <li>Asthma</li> <li>COPD</li> <li>Interstitial Lung Disease</li> <li>Cystic Fibrosis</li> <li>Patients Requiring Lung Transplant</li> </ul>		Airway Disease Section, National Heart and Lung Institute, Imperial College, London, United Kingdom
21	ENOSE in Pulmonary Tuberculosis in Yogyakarta	Completed	No Results Available	<ul> <li>Pulmonary Tuberculosis Suspected</li> <li>Other Specified Chronic Obstructive Pulmonary Disease</li> <li>Pulmonary Tuberculosis TB (+) Histology, (-) Bacteriology</li> </ul>	Other: 5 min exhaled breath sampling with soft nose clamp	•patients - at 5 lung clinics (Minggiran, Kalasan, Kotagede, Bantul, Kuonprogo) connected with Sudjarto Teachnig Hospital; healthy controls among students and staff of Hospital and Gadjah Mada Universitas, Yogyakarta, Jalan Kesehatan no.1, Yogyakarta, Indonesia
22	The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases	Terminated	No Results Available	<ul><li>Asthma</li><li>Respiratory Candidiasis</li><li>Respiratory Aspergillosis</li><li>COPD</li><li>Bronchiectasis</li></ul>	Drug: PC945     Drug: Placebo	Glenfield Hospital, Leicester, United Kingdom     Royal Liverpool University Hospital, Liverpool, United Kingdom     Royal Brompton Hospital, London, United Kingdom     Northwest Lung Research Centre, Manchester, United Kingdom

	Title	Status	Study Results	Conditions	Interventions	Locations
23	EfiKroniK Research Program: Physical Exercise for People With Chronic Pathologies	Recruiting	No Results Available	<ul> <li>Neoplasms</li> <li>Schizophrenia</li> <li>COPD</li> <li>Physical Activity</li> <li>Quality of Life</li> <li>Primary Care</li> </ul>	Other: Personalized Supervised physical activity	Primary care research unit of Bizkaia, Bilbao, Bizkaia, Spain
24	Nutritional Supplementation in Adults With Chronic Respiratory Disease	Completed	No Results Available	<ul> <li>Malnutrition</li> <li>Pulmonary Disease, Chronic Obstructive</li> <li>Other Pulmonary Disease, Chronic Obstructive</li> </ul>	Dietary Supplement: Complete enteral formula     Other: Dietary Advise	Clínica San Gabriel, San Miguel, Lima, Peru
25	Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease	Recruiting	No Results Available	<ul> <li>Asthma</li> <li>COPD</li> <li>Interstitial Lung Disease</li> <li>Cystic Fibrosis</li> <li>Pulmonary Hypertension</li> <li>Pulmonary Infection</li> <li>Other Lung Disease</li> </ul>	Drug: Hyperpolarized Xe129	University of Kansas Medical Center, Kansas City, Kansas, United States
26	Study of Default Options in Advance Directives	Completed	No Results Available	*COPD     *Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy     *Idiopathic Pulmonary Fibrosis     *Other Interstitial Lung Disease Without Curative Therapy     *Congestive Heart Failure     *NYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past Year     *Malignancy     *Any Stage 3B or 4 Solid Tumor	Other: Comfort Default AD forms Other: Life Extension Default AD forms Other: Standard Default AD forms	Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, United States

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services